UTHR insider notice: 90,000 shares ($40.78M) to be sold on 10/06/2025
Rhea-AI Filing Summary
United Therapeutics (UTHR) filed a Form 144 reporting a proposed sale of 90,000 common shares, to be executed through Morgan Stanley Smith Barney LLC on 10/06/2025 on NASDAQ. The shares were acquired and paid for on 10/06/2025 through an exercise of stock options and funded in cash. The filing lists the aggregate market value of the shares as $40,776,300.00 and total shares outstanding as 45,226,262.
The notice also discloses multiple Rule 10b5-1 sales attributed to Michael Benkowitz during September 2025 totaling several transactions (examples: 7,875 and 14,625 share blocks) with gross proceeds reported per trade. The filer affirms no undisclosed material nonpublic information and includes the standard signature/attestation language required by the form.
Positive
- Transaction transparency: Form 144 discloses the full sale amount of 90,000 shares and $40,776,300.00 aggregate market value
- Use of 10b5-1 plans for prior September 09/2025 sales indicates pre-arranged disposition consistent with compliance practices
Negative
- Large block relative to float: 90,000 shares represent a notable package against 45,226,262 outstanding shares
- Concentration of sales by an insider in a short period (09/2025 trades plus this 10/06/2025 sale) could increase short-term supply pressure
Insights
TL;DR: An insider plans a large post-exercise sale of newly exercised options alongside recent 10b5-1 trades.
The filing reports the proposed sale of 90,000 shares acquired by exercise of stock options on 10/06/2025
These shares carry an aggregate market value of $40,776,300.00, representing a meaningful block versus the reported 45,226,262 outstanding shares. Recent 10b5-1 sales by Michael Benkowitz in 09/2025 show systematic disposition activity in smaller tranches with material gross proceeds per trade.
Key dependencies include the execution price and timing on 10/06/2025 and whether additional scheduled 10b5-1 trades remain active; monitor transaction settlement and exchange reporting within days following the stated sale date.
TL;DR: The Form 144 is procedural and includes the standard attestation against undisclosed material information.
The notice uses the required attestation language that the selling person does not possess undisclosed material adverse information as of the signatory date. The sale is routed through Morgan Stanley Smith Barney LLC and is designated for NASDAQ execution on 10/06/2025.
From a governance perspective, the presence of documented 10b5-1 sales in 09/2025 supports a pre-arranged trading plan for at least one insider. Confirmatory filings and broker confirmations after 10/06/2025 will complete the public record for compliance review.